• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CytoMed Therapeutics Limited - Ordinary Shares (NQ:GDTC)

    0.8560 -0.0140 (-1.61%)
    Delayed Quote Updated: 12:30 PM EDT, Oct 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,325
    Open 0.9400
    Bid (Size) 0.8400 (900)
    Ask (Size) 0.8765 (800)
    Prev. Close 0.8700
    Today's Range 0.8401 - 0.9400
    52wk Range 0.6801 - 3.680
    Shares Outstanding 11,540,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector
    Via Get News

    Performance

    52-Week Range 76.7% below 52-week high
    0.8560
    0.6852W Low 3.6852W High
    1 Week 13.0% below 1-week high
    0.711W Low 0.981W High

    CytoMed Therapeutics Limited - Ordinary Shares (GDTC) traded between $0.68 and $3.68 over the past 52 weeks and last traded at $0.86, 76.7% below its 52-week high. Over the past week it ranged between $0.71 and $0.98.

    Past 12 Months
    -3.8%
    +6.3%
    -16.1%
    -16.1%
    -38.4%
    -62.0%
    1W -$0.03
    1M +$0.05
    3M -$0.16
    6M -$0.16
    YTD -$0.53
    1Y -$1.39

    GDTC was -62.0% over the past year, -16.1% over six months, -38.4% year to date, -3.8% in the last week.

    12 Months vs Market
    GDTC
    -62.0%
    DIA
    +12.3%
    SPY
    +15.0%
    QQQ
    +18.4%
    IWM
    +8.2%

    Over the past 12 months GDTC returned -62.0% versus DIA (Dow) +12.3%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +18.4% and IWM (Russell 2000) +8.2%.

    Volume & Liquidity 0.04× 3-mo avg
    Today 3,325 3-mo avg 80.3K
    1W
    22.7K
    1M
    20.4K
    3M
    80.3K
    6M
    50.2K
    YTD
    206.1K
    1Y
    185.1K

    GDTC most recently traded 3,325 shares against a 3-month average daily volume of 80.3K.

    More News

    Read More
    News headline image
    CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector
    Via Get News
    News headline image
    CytoMed, a Singapore Biotech, Revolutionizes Cancer Treatment Using Donor Immune Cells
    Via Get News
    Unusual volume stocks in Thursday's session ↗
    Via Chartmill
    News headline image
    CytoMed Therapeutics Ltd – A Rising Star in Singapore’s Cancer Biotechnology Sector
    Via Get News
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    Thursday's session: top gainers and losers ↗
    Via Chartmill
    Discover the top movers in Thursday's pre-market session. ↗
    Via Chartmill
    Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
    Via Chartmill
    News headline image
    CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Why Did CytoMed Therapeutics Stock Jump 19% Today? ↗
    Via Stocktwits
    News headline image
    CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire

    Frequently Asked Questions

    Is CytoMed Therapeutics Limited - Ordinary Shares publicly traded?
    Yes, CytoMed Therapeutics Limited - Ordinary Shares is publicly traded.
    What exchange does CytoMed Therapeutics Limited - Ordinary Shares trade on?
    CytoMed Therapeutics Limited - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares?
    The ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares is GDTC on the Nasdaq Stock Market
    What is the current price of CytoMed Therapeutics Limited - Ordinary Shares?
    The current price of CytoMed Therapeutics Limited - Ordinary Shares is 0.8560
    When was CytoMed Therapeutics Limited - Ordinary Shares last traded?
    The last trade of CytoMed Therapeutics Limited - Ordinary Shares was at 10/16/26 12:30 PM ET
    What is the market capitalization of CytoMed Therapeutics Limited - Ordinary Shares?
    The market capitalization of CytoMed Therapeutics Limited - Ordinary Shares is 9.88M
    How many shares of CytoMed Therapeutics Limited - Ordinary Shares are outstanding?
    CytoMed Therapeutics Limited - Ordinary Shares has 10M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.